{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:15:22Z","timestamp":1791450922316,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) are considered as laboratory markers of inflammation. They can be potentially useful in predicting the course of multiple neoplasms including selected hematological cancers. The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen. The study group consisted of 100 patients treated with the first line CTD (cyclophosphamide, thalidomide, and dexamethasone) chemotherapy. The NLR and PLR were calculated before treatment. High NLR was observed in patients with higher stage of the disease, with poor performance status, hypercalcemia, and high CRP. High PLR was associated with low BMI and high CRP. In patients with high NLR, significantly shorter PFS was observed (17 vs. 26\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0405). In addition, high values of NLR and PLR were associated with significantly shorter OS (38 vs. 79\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0010; 40 vs. 78\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0058). Summarizing, NLR and PLR have a significant independent prognostic value for multiple myeloma patients. Furthermore, the NLR can be a predictive marker for the outcome of thalidomide-based chemotherapy.\n                  <\/jats:p>","DOI":"10.1007\/s00277-020-04092-5","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T17:04:25Z","timestamp":1590512665000},"page":"2881-2891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-394X","authenticated-orcid":false,"given":"Aneta","family":"Szudy-Szczyrek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Szczyrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nowaczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Homa-Mlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Zmorzy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Ku\u015bmierczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Sompor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Filip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ma\u0142ecka-Massalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"12","key":"4092_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"5","key":"4092_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28(5):1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia."},{"issue":"15","key":"4092_CR3","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"issue":"26","key":"4092_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"1","key":"4092_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 23(1):10\u201324. https:\/\/doi.org\/10.1038\/leu.2008.259","journal-title":"Leukemia."},{"issue":"6","key":"4092_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell. 140(6):883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell."},{"issue":"5","key":"4092_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell."},{"issue":"9","key":"4092_CR8","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1172\/JCI80007","volume":"125","author":"S Shalapour","year":"2015","unstructured":"Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347\u20133355. https:\/\/doi.org\/10.1172\/JCI80007","journal-title":"J Clin Invest"},{"issue":"10","key":"4092_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","volume":"36","author":"D Wang","year":"2015","unstructured":"Wang D, DuBois RN (2015) Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 36(10):1085\u20131093. https:\/\/doi.org\/10.1093\/carcin\/bgv123","journal-title":"Carcinogenesis."},{"issue":"1","key":"4092_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24\u201337. https:\/\/doi.org\/10.1038\/nrc1782","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4092_CR11","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.4049\/jimmunol.141.12.4395","volume":"141","author":"HY Shau","year":"1988","unstructured":"Shau HY, Kim A (1988) Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141(12):4395\u20134402","journal-title":"J Immunol"},{"issue":"3","key":"4092_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0092-8674(00)00139-2","volume":"103","author":"LM Coussens","year":"2000","unstructured":"Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 Supplied by Bone Marrow\u2013Derived Cells Contributes to Skin Carcinogenesis. Cell. 103(3):481\u2013490. https:\/\/doi.org\/10.1016\/S0092-8674(00)00139-2","journal-title":"Cell."},{"issue":"3","key":"4092_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1245\/s10434-008-0267-6","volume":"16","author":"Y Kishi","year":"2009","unstructured":"Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey J-N (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614\u2013622. https:\/\/doi.org\/10.1245\/s10434-008-0267-6","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4092_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12032-014-0311-2","volume":"31","author":"LMA el Aziz","year":"2014","unstructured":"el Aziz LMA (2014) Blood neutrophil\u2013lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Med Oncol 31(12):311. https:\/\/doi.org\/10.1007\/s12032-014-0311-2","journal-title":"Med Oncol"},{"issue":"2","key":"4092_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","volume":"10","author":"NA Cannon","year":"2015","unstructured":"Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280\u2013285. https:\/\/doi.org\/10.1097\/JTO.0000000000000399","journal-title":"J Thorac Oncol"},{"issue":"7","key":"4092_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204\u20131212. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0146","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"4092_CR17","doi-asserted-by":"publisher","first-page":"e101119","DOI":"10.1371\/journal.pone.0101119","volume":"9","author":"X Zhou","year":"2014","unstructured":"Zhou X, Du Y, Huang Z et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 9(6):e101119. https:\/\/doi.org\/10.1371\/journal.pone.0101119","journal-title":"PLoS One"},{"issue":"3","key":"4092_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF02573067","volume":"9","author":"M Ikeda","year":"2002","unstructured":"Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9(3):287\u2013291. https:\/\/doi.org\/10.1007\/BF02573067","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4092_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-018-5264-y","volume":"19","author":"D Nie","year":"2019","unstructured":"Nie D, Yang E, Li Z (2019) Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis. BMC Cancer 19(1):73. https:\/\/doi.org\/10.1186\/s12885-018-5264-y","journal-title":"BMC Cancer"},{"issue":"2","key":"4092_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","volume":"18","author":"MR Reagan","year":"2012","unstructured":"Reagan MR, Ghobrial IM (2012) Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin cancer Res an Off J Am Assoc Cancer Res 18(2):342\u2013349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2212","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"5","key":"4092_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00277-013-1978-8","volume":"93","author":"E Kelkitli","year":"2014","unstructured":"Kelkitli E, Atay H, Cilingir F et al (2014) Predicting survival for multiple myeloma patients using baseline neutrophil\/lymphocyte ratio. Ann Hematol 93(5):841\u2013846. https:\/\/doi.org\/10.1007\/s00277-013-1978-8","journal-title":"Ann Hematol"},{"key":"4092_CR22","doi-asserted-by":"publisher","unstructured":"Onec B, Okutan H, Albayrak M et al (2017) The predictive role of the neutrophil\/lymphocyte ratio in survival with multiple myeloma: a single center experience. J Clin Lab Anal 31(2). https:\/\/doi.org\/10.1002\/jcla.22032","DOI":"10.1002\/jcla.22032"},{"issue":"11","key":"4092_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","volume":"94","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, di Raimondo F, Borrello I (2015) Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol 94(11):1875\u20131883. https:\/\/doi.org\/10.1007\/s00277-015-2462-4","journal-title":"Ann Hematol"},{"key":"4092_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/OTT.S153146","volume":"11","author":"S Mu","year":"2018","unstructured":"Mu S, Ai L, Fan F, Sun C, Hu Y (2018) Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther 11:499\u2013507. https:\/\/doi.org\/10.2147\/OTT.S153146","journal-title":"Onco Targets Ther"},{"issue":"41","key":"4092_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012678","volume":"97","author":"Q Zeng","year":"2018","unstructured":"Zeng Q, Liu Z, Li Q, Liu T (2018) Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: a meta-analysis. Medicine (Baltimore) 97(41):e12678. https:\/\/doi.org\/10.1097\/MD.0000000000012678","journal-title":"Medicine (Baltimore)"},{"key":"4092_CR26","doi-asserted-by":"publisher","unstructured":"Li Y, Li H, Li W et al (2017) Pretreatment neutrophil\/lymphocyte ratio but not platelet\/lymphocyte ratio has a prognostic impact in multiple myeloma. J Clin Lab Anal 31(5). https:\/\/doi.org\/10.1002\/jcla.22107","DOI":"10.1002\/jcla.22107"},{"issue":"12","key":"4092_CR27","doi-asserted-by":"publisher","first-page":"18792","DOI":"10.18632\/oncotarget.13320","volume":"8","author":"L Shi","year":"2017","unstructured":"Shi L, Qin X, Wang H et al (2017) Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 8(12):18792\u201318801. https:\/\/doi.org\/10.18632\/oncotarget.13320","journal-title":"Oncotarget"},{"issue":"4","key":"4092_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/JLP.JLP_36_18","volume":"10","author":"S Solmaz","year":"2018","unstructured":"Solmaz S, Uzun O, Acar C, Sevindik OG, Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA, Alacacioglu I (2018) Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? J Lab Physicians 10(4):363\u2013369. https:\/\/doi.org\/10.4103\/JLP.JLP_36_18","journal-title":"J Lab Physicians"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04092-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:28:37Z","timestamp":1696156117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04092-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04092-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Medical University of Lublin (Approval No. KE-0254\/77\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"All patients provided written informed consent"}}]}}